1. Introduction {#sec0005}
===============

The current opioid overdose crisis is characterized by surging and unprecedented rates of overdose and has been linked to contamination of fentanyl and carfentanil in the drug supply ([@bib0090]; [@bib0075]; [@bib0315]). Socioeconomic marginalization (SEM) and the vulnerability it creates is an important but under-explored contributor to overdose for people who use opioids. While general knowledge of the social determinants of health is widely established, connecting upstream elements of marginalization to acute health crisis events like opioid overdose has not been done systematically: an omission we aim to contribute to resolving in this paper. Without this understanding, developing specific responses to the opioid and overdose crises through evidence-based interventions on the elements of marginalization that are most tightly linked to overdose is not possible. This paper presents the results of a review designed to systematically summarize evidence on SEM and opioid-related overdose.

We define SEM as a set of conditions that contribute to exclusion from social and economic opportunities and create vulnerability including: labour market exclusion; informal or prohibited income generation (e.g. theft, drug dealing, street-based work); material insecurity (e.g. housing or food insecurity); inadequate income; incarceration; social stigma or isolation; and low socioeconomic status or poverty. Conditions that may contribute to SEM have been linked to overdose, with specific subpopulations of people who use drugs at elevated risk of drug-related death, including people who are homeless ([@bib0105]), have been recently released from prison ([@bib0120]; [@bib0290]), are eligible for US Medicaid (a proxy indicator of poverty) ([@bib0070]), are of Indigenous ancestry ([@bib0155]; [@bib0190]), grew up in a low-income household ([@bib0110]; [@bib0170]; [@bib0285]), or did not complete high school ([@bib0110]; [@bib0135]; [@bib0170]; [@bib0285]). However, these factors insufficiently represent the scope of socioeconomic drivers that affect the health and overdose risk for people who use opioids such as labour market exclusion ([@bib0240] ;[@bib0245]), involvement in illegal and informal income generation ([@bib0295]), synchronized administration of income assistance payments ([@bib0165]; [@bib0220]; [@bib0325]), and material insecurity ([@bib0215]) -- all of which have received inadequate attention in overdose research ([@bib0035]). These factors are hypothesized to affect health outcomes not only through direct material deprivation, but also through psychosocial and behavioural pathways ([@bib0035]). The chronic stress that comes from social exclusion, diminution, and inequality promote stress responses that can lead to increased interpersonal conflict and ill health, cyclically reinforcing the distributions of power that create them ([@bib0035]). Social and economic components of marginalization, including access to the resources and conditions that affect drug-related harm such as neighborhood deprivation and income inequality are associated with overdose and drug-related death not just at the individual level, but also structurally through the control and distribution of socio-economic resources ([@bib0165]; [@bib0170]; [@bib0220]; [@bib0250]; [@bib0320]; [@bib0325]). The confluence of factors involved in these relationships make it difficult to isolate root causes. However, the patterns visible between these conditions and their effect on overdose exemplify the multiple types of disadvantage--- spatial and cumulative life course disadvantage, for example --- that together affect health inequities for people who use opioids.

A better understanding of these relationships is important for developing responses to the opioid and overdose crises that intervene on upstream determinants of health, yet there are no systematic reviews that summarize specific risks linking social and economic factors to the production or magnification of overdose risk for people who use opioids. This is a critical gap, limiting our knowledge of the socioeconomic drivers of opioid-related overdose and which dimensions would be most effectively and efficiently targeted with response strategies. We conducted this systematic review of the literature to help address these omissions, with the aim of summarizing the scientific evidence about the associations between socioeconomic factors and opioid overdose.

2. Methods {#sec0010}
==========

2.1. Search strategy and selection criteria {#sec0015}
-------------------------------------------

In accordance with the Systematic Reviews and Meta-Analyses (PRISMA) guidelines, we searched for studies that included measures of socioeconomic factors and opioid-related fatal and non-fatal overdose that were published in English peer-reviewed journals or by governmental sources between January 1, 2000 -- March 31, 2018. The search strategy is summarized in [Table 1](#tbl0005){ref-type="table"} and a summary of the Medline search terms is outlined in Appendix A. The protocol was registered in the PROSPERO database (registration\# CRD42018096392) prior to beginning the review ([@bib0300]).Table 1Systematic Review Search Strategy and PICOS Criteria.Table 1Search Concepts\*SEM: Social class, socioeconomic status; low education; unemployment, labour market exclusion; material insecurity, material hardship; housing insecurity, homelessness, unstable housing; hunger, food insecurity; health care access, social service access; poverty and income inadequacy; social assistance, income assistance, welfare, disability; prohibited income generation (e.g. theft, drug dealing, street-based work); early childhood development; incarceration, criminal justice system involvement; persistent disadvantage, vulnerability, stigma, social isolation, social exclusion, marginalization; service barriers and availability, location of social services, health care service availability and accessibility; housing availability, housing affordability; urbanization, neighborhood disorder; disparities, income inequality, wealth inequality, neighborhood median income; synchronized social assistance, ("cheque day effect" or "check effect"); welfare, disability, and income assistance policies; criminal justice and drug policies.\
Overdose (fatal and non-fatal): poisoning, drug-related poisoning, side-effects/adverse reactions, toxicity, death, morbidity, mortality, overdose\
Opioids: People who use opioids (medical/non-medical), prescription and non-prescription, oral and injectionDatabasesMEDLINE (Ovid), Embase (Ovid), PsycINFO (EBSCOhost), CINAHL (EBSCOhost), Google Scholar, Cochrane Central Registry of Controlled Trials (CENTRAL), and Cochrane Drug and Alcohol Group (CDAG) Specialized RegistryOther Search StrategiesIn addition to searching electronic databases, additional searches on clinicaltrials.gov, a comprehensive grey literature search (e.g., [www.opengrey.eu](http://www.opengrey.eu){#intr0005}, <https://deslibris.ca>), conference proceedings (e.g., Harm Reduction International, American Public Health Association, etc.), and manual searches of the references of included studies other reviews in this area, and studies that have cited the included studies were performed. The search strategy also included contacting experts and community stakeholders to identify unpublished, ongoing and other studies not otherwise retrieved through searches for this review.PICOS CriteriaPopulation: People who use opioids in North America, Europe, the United Kingdom, Australia, and New Zealand. Articles were only included if they had opioids identified as a cause of overdose. Poly drug-related overdose papers were included if they included opioid overdose in the cases.\
Intervention: Any measure of socioeconomic marginalization as an independent variable in the article (i.e. labour market exclusion; informal or prohibited income generation; material insecurity; inadequate income; incarceration; social stigma or isolation; and low socioeconomic status or poverty). Articles were included if they had any measure of socioeconomic marginalization as an independent variable in the article. Articles that include socio-demographic variables as controls in their multivariable regression models, for example, were included as long as there were empirical results that showed the effects of the SEM variables on opioid overdose.\
Comparison: Quantitative studies with comparisons between groups with different levels of social and economic marginalization\
Outcomes: Opioid-related fatal and non-fatal overdose. Articles were included only if they had overdose as a unique/isolated outcome. Articles examining drug-related harm or mortality might include overdose but also include death or harm from other factors (e.g., motor vehicle accidents) and as such were excluded.\
Study design: Any study design including quantitative data. Articles that contained empirical data were included. Case-reports, letters, commentaries, reviews, and editorials were excluded.[^1]

We used the PICOS framework (Population, Intervention, Comparison, Outcome, Study Design) to frame our research question ([@bib0255]) and searched for studies among people who use opioids (P) that contained any measure of socioeconomic marginalization (I) with comparisons (C) between groups with different levels of social and economic marginalization and opioid-related fatal and non-fatal overdose (O) using quantitative data (S). Two research assistants used a standardized form to independently extract data from the studies, and any inconsistencies in the extracted data were noted by the research assistants and resolved through final deliberation by a senior team member.

2.2. Data analysis {#sec0020}
------------------

Given that this review asked a broad question and purposely allowed inclusion of different study types, we used the \'lumping\' technique where all studies in a topic area were included despite design differences ([@bib0145]; [@bib0125]). Similar to the approach taken by others investigating determinants of overdose ([@bib0160]), this strategy was employed to identify common generalizable features in the relationships between SEM and opioid overdose that remain despite minor differences in study subjects, context, and design. The choice to take a broad approach, combining heterogenous outcome measures was made to allow for the generalisability and consistency of research findings to be assessed across a wider range of different outcomes: reducing the risk of bias or chance results.

Due to significant variations in methodologies and outcomes of studies included in this systematic review, findings are summarized according to elements of SEM. The conceptual and methodological heterogeneity across the studies precluded the undertaking of a meta-analysis. The data extraction sheet included an additional assessment of bias and study quality, for which we used the tested and validated study quality assessment tools of the National Heart, Lung, and Blood Institute ([@bib0200]).

3. Results {#sec0025}
==========

3.1. Study selection and study characteristics {#sec0030}
----------------------------------------------

The process to select studies is detailed in the PRISMA flow diagram in [Fig. 1](#fig0005){ref-type="fig"} . A total of 5782 articles met the initial screening criteria. The review and screening process led to a final dataset of 37 articles. Substantial heterogeneity was seen between both the types of overdose outcome reported and the method of operationalization for each dimension of SEM in included studies. Half of the included studies (n = 19) focused on fatal overdose as a key outcome or drew their sample from a population who had had a fatal overdose (see [Table 4](#tbl0020){ref-type="table"} for details on overdose outcome, intent, type of opioid, and measure of SEM included). One third included non-fatal overdose (n = 13) and five articles included both fatal and non-fatal overdose in their analyses. In terms of intent, 11 articles examined only unintentional overdose, nine examined both intentional and unintentional overdose and 17 did not report intention. Half the studies included overdose that was attributable to both prescription and non-prescription opioids in their sample (n = 19) while nine investigated prescription opioid overdose and four investigated only non-prescription opioid overdoses. Five studies did not report what type of opioids were included in their data. Nineteen studies used cross-sectional data, eight studies used cohort data, six studies used longitudinal data, two studies used case-control designs, one study used an interrupted time series, and one study used ecological data (see [Table 3](#tbl0015){ref-type="table"} for details on study design for each included study).Fig. 1PRISMA Flow Diagram.Fig. 1

The included studies covered a wide range of topics, and included variables related to eight elements of SEM: criminal justice system involvement (n = 13); income (n = 13); employment (n = 11); social support (n = 9); health insurance (n = 8); housing/homelessness (n = 8); education (n = 8); and composite measures of socio-economic status or deprivation (n = 6). A summary of measures and findings as well as risk of bias assessments for the 37 included studies can be found in [Table 4](#tbl0020){ref-type="table"}.

3.2. Risk of bias within included studies {#sec0035}
-----------------------------------------

Each study was evaluated across a set of domains to assess risk of bias, the results of which can be seen in [Table 2](#tbl0010){ref-type="table"} . Serious concerns related to risk of bias were present, and the way the literature from observational cohort and cross-sectional studies performs on each metric in aggregate can be seen visually in [Fig. 2](#fig0010){ref-type="fig"} . Many studies only measured exposure variables once during the study; had a lack of multivariate controls for confounding variables; did not include information about power, effect estimates, or a sample size justification; or reported bivariate relationships only. The dataset thus is largely observational with no experimental study designs in the pool of included papers, allowing for conclusions to be drawn about the correlations and statistical associations present between variables in the data but not about causal pathways identifying how SEM impacts opioid overdose. The absence of significant findings in some studies should not be interpreted as there being no relationship between these factors, particularly considering the risk of bias within the referenced studies, the quality of measures included, and the type of analysis conducted. Similarly, it is possible that positive relationships identified are also due to bias within the studies rather than a true relationship.Table 2Summary of Risk of Bias Assessments for Included Studies. (For interpretation of the references to colour in this table, the reader is referred to the web version of this article.)Table 2![](fx1_lrg.gif)[^2][^3][^4][^5][^6][^7][^8][^9][^10][^11][^12][^13][^14][^15][^16][^17][^18][^19][^20][^21][^22][^23][^24][^25][^26][^27][^28][^29][^30]Table 3Study Design and Sample Characteristics of Included Studies.Table 3First Author (Year)Study design/ LocationSample characteristicsEthnicityRecruitment and data source[@bib0010]Cross-sectional/ NorwayN: 1628\
Age: Mean: 38.4;\
Sex: 76.4 % maleNR- Norwegian Cause of Death Registry (2003--2009)\
- linked to administrative databases[@bib0015]Cohort/ USAN: 30,237;\
Age: Mean (SD): 33.4 (9.8);\
Sex: 87.0 % maleWhite, non-Hispanic: 62 %; Black, non-Hispanic: 20 %; Hispanic: 13 %;\
Native American, Alaska Native, non-Hispanic: 3%;\
Asian or Pacific Islander, non-Hispanic: 2%- Washington State Department of Corrections (1999--2003)\
- linked to National Death Index[@bib0020]Longitudinal data/ USA\*N: 74 police precincts; Age: Mean percent under 35 (SD): 51.2 % (7.5);\
Sex: Mean percent male (SD): 47.0 % (2.3) male\*Black: Mean percent (SD): 27.5 % (27.2)- Office of the Chief Medical Examiner data in New York[@bib0025]Cross-sectional/ USAN: 530;\
Age:18−39: 45.3%,\
40+: 54.7 %;\
Sex: 70.9 % maleWhite: 90.2 %;Non-white: 9.8 %- Rhode Island Office of Medical Examiner Data\
- Linked to Rhode Island Department of Corrections[@bib0040]Cross-sectional/ AustraliaN: 163;\
Age: Median: 21;\
Sex: 54.0 % maleNR- Survey with young people (15--30 years) who used heroin from three inner-metropolitan Melbourne general practices (June - December 2000)\
- linked to the Pharmaceutical Benefits Scheme[@bib0030]Longitudinal data/ USAN: 50 states;\
Age: Mean: NR;\
Sex: NRNR- CDC's Detailed Mortality File (1999−2014)\
- US Census Bureau Population Survey\
- Freddie Mac House Price Index[@bib0045]Cohort/ USAN: 396,452;\
Age: Mean: 51.83;\
Sex: 41.0 % maleHispanic: 17.2 %; Asian: 9.7 %; Black: 9.4 %; Multi-racial: 4.5 %;\
Native American: 0.6 %; Other or unknown: 1.8 %; White: 56.8 %- Kaiser Permanente Northern California Electronic Health Records database (2011−2014)[@bib0050]Cross-sectional/ ItalyN: 265;\
Age: Mean (SD): 35.4 (9.4);\
Sex: 79.0 % maleNR- Therapeutic community program participants\
- Completed survey for the Psychiatric and Addictive Dual Disorders in Italy project (2010)[@bib0055]Case control/ USAN: 6413; Age:15−44 :58.9%,45−64: 41.1 %,\
Sex: 77.9 % maleWhite: 39.6 %; Black: 25.7 %; Hispanic: 29.7 %- Office of the Chief Medical Examiner New York (2000−2006)[@bib0060]Cross-sectional/ USAN: 254;\
Age:18−44 years:57.5%,\
45 years or older:42.5 %;\
Sex: NRWhite: 98.3 %; Black: 0.4 %; Other: 0.8\
%- Prescription Pain Medication Dataset from the Utah Department of Health (2008−2009)\
- Office of the Medical Examiner\
- linked to the Labour Commission database[@bib0065]Cohort/ USAN: 297,634;\
Age:18−29:47.3%,30−64: 52.7 %;\
Sex: 28.7 % maleWhite: 56.2 %; Black: 28.2 %; Hispanic: 12.1 %; Other: 3.6 %- Medicaid records from Pennsylvania Department of Human Services (2010−2012)[@bib0070]Cross sectional/ USAN: 1668\
Age: \<18−44: 50.5%,\
45--65+: 49.5;NR- Washington State Department of Health (2004−2007)[@bib0080]Cross-sectional/ USAN: 478;\
Age: Mean (SD): 35.7 (11.1);\
Sex: 67.3 % maleWhite: 44.4 %; Black: 52.9 %; Other: 2.7 %- Survey with criminal justice involved individuals who reported to a community corrections office for drug monitoring (2012)[@bib0085]Cross-sectional/ USAN: 345; Age: 29.1 % older than 50 years;\
Sex: 44.8 % maleCaucasian: 60.0 %; Hispanic: 3.5\
%- Survey with methadone maintenance clinic and syringe program participants[@bib0095]Cross-sectional/ USAN: 9647; Age: -20\
−34: 42.0%,\
35--55+: 57.9 %; Sex: 48.0\
% maleNon-Hispanic White: 73.9 %;\
Non-Hispanic Black: 9.5 %; Hispanic: 9.4 %; Other: 7.3\
%- Nevada State inpatient and emergency department databases (2011−2013)\
- linked to the US census five year (2009−2013) American Community Survey[@bib0100]Cohort/ USAN: 358;\
Age: 18--44: 57.5 %; 45--64: 42.5 %, Sex: 41.5 % maleWhite: 84.1 %; Other:15.9 %- Montana's Office for Vital Records and Montana Medicaid enrolment records (2003−2012)[@bib0130]Cohort/ USAN: 19,709;\
Age: Median (IQR): 42 (27−55); Sex: 43.0% maleNon-Hispanic White: 69 %;\
Non-Hispanic Black: 9%;\
Hispanic: 15 %; Other: 4%- California and Florida State Emergency Department Databases and State Inpatient Databases (2010−2011)[@bib0140]Longitudinal data/ USAN: 3138 counties;\
Age: NA; Sex: NANR- State Emergency Department Databases\
- CDC Multiple Cause of Death files[@bib0150]Cross-sectional/ USAN: 443;\
Age: Mean (SD): 38 (12);\
Sex: 71.0 % maleWhite: 73 %; African-American: 8%; Native American, Alaska Native: 5%; Native Hawaiian, Pacific Islander: 1%; Asian, South Asian: 1%; Latino, Hispanic: 6%; Multi-racial: 6%- Surveys for individuals using syringe exchange sites in King County and Seattle, Washington[@bib0175]Ecological/ USAN: 1065;\
Age: 0--44: 48.8 %,45--65+: 51.2 %;\
Sex: 61 % maleHispanic: 12 %;White: 84 %;Asian: 2.4 %;Black: 1.7 %-Orange County Coroner Division's data file (2010−2014)[@bib0180]Cross-sectional/ United KingdomN: 291;\
Age: Mean (SD): 33.5 (8.9);\
Sex: 82.1 % maleNR-Drug-related death monitoring data from two Scottish National Health Service Board areas (2006−2007)[@bib0185]Cross sectional/ USAN: 1540\
Age: \<18−34: 68.1%,\
35--55+: 31.9 %;\
Sex: 71.1 % maleBlack: 12.7 %;White: 77.2 %;Other: 5.1 %-Wisconsin Division of Public Health's emergency department visit and hospital discharge datasets (2003--2012)[@bib0195]Nested case-control/ USAN: 45,153;\
Age: 18−54: 60.0%,55−65+: 40.0 %;Sex: 52.1\
% maleNon-Hispanic White: 56.8 %;\
Non-Hispanic Black: 15.4 %;Hispanic: 5.2 %;Other: 22.7\
%-PharMetrics Plus data set from the IMS Health Real-World Data Adjudicated Claims--US Database[@bib0205]Cross-sectional/ USAN: 795\
Age: 15−19: 23.1%20−24: 51.1 %25−29: 25.8 %;Sex: 66.8\
% maleCaucasian: 80.4 %;\
Native American:1.1 %;\
African--American: 2.3 %; Asian/Pacific Islander: 0.6 %; Hispanic 3.6 %; Mixed, other: 10.9 %- Survey with participants were who were \<30 years old and had injected once or more in the prior month recruited using street outreach and snowball techniques[@bib0210]Cohort/ NorwayN: 338\
Age: Mean: 25.6 \[Men\];\
24.3 \[Women\];\
Sex: 72 % maleNR- Survey with participants receiving treatment at the State Clinic for Drug Addicts (1981−1991)[@bib0225]Interrupted time-series/ USAN: 343−34 (states)\
Age: NR;\
Sex: NRNR-State prescription drug monitoring programs (\<2011)\
-National Alliance for State Model Drug Laws (2012−2013)[@bib0230]Cross-sectional/ USAN: Methadone (n = 87)\
Other Opioids (n = 163)\
Age: 18−34: 38.4%35−45+: 61.6 %;Sex: 67.6\
% maleNR- Coroner's data from West Virginia (2006)\
-West Virginia Controlled Substances Monitoring Program[@bib0235]Longitudinal data/ USAN: 5513\
Age: Mean (SD):\
0−19: 27.59 (4.53) 20−24: 7.37 (1.05) 25−44: 25.55 (4.85) 45−64: 24.70 (3.33)\
Sex: 49.6 % maleNR-Nebraska and South Dakota inpatient hospital discharges (2007−2012)[@bib0250]Cohort/AustraliaN: 172\
Age: \<18−44: 59.3%45−65+: 40.8 %Sex: 58.1\
% maleNR-National Coroners Information System (NCIS) Victorian Drugs Module (VDM; 2003)\
-VIFM toxicology database (\<2003)[@bib0260]Cross-sectional/ USAN: 1427\
\<39: 406 (28.5 %)40−50+: 1021 (71.5 %)Black: 51.3 %;White: 35.2 %;Latino: 7.3 %;\
Asians, Pacific Islanders, Native Americans, and Mixed: 6.1 %-Survey with street recruited people who inject drugs in San Francisco Bay Area, California[@bib0265]Longitudinal data/ USAN: 1120\
Age: \<15 to 44: 67.0 %;45--70+: 33.0 %;Sex: 77.4\
% maleWhite, non-Hispanic: 42.0 %; Hispanic: 52.5 %;\
American Indian: 2.0 %;\
Black or Asian: 2.9 %-Office of the Medical Investigator and the Toxicology Bureau of the Scientific Laboratory Division, New Mexico Department of Health (1998−2002)[@bib0270]Longitudinal data/ USAN: NR\
Age: \<15−85+\
Sex: NRNR-New York state vital statistics multiple-cause-of-death data\
- New York state Medicaid enrollment data.[@bib0275]Cohort/ USAN: NR\
Age: Median (IQR) in group Experienced overdose (n = 90):\
Yes: 28.7 (26.0, 31.5);\
No: 29.1 (25.9, 33.0);\
Sex: 56.7 % maleRace in group experienced OD:\
African American:\
Yes: 18.0 %;No: 45.4\
%-Survey with young people who use drugs in the Risk Evaluation and Assessment of Community Health III (REACH III) cohort (1999−2002)[@bib0280]Cross-sectional/ USAN: 2649\
Age:15--44: 48.2 %; 45--84: 51.7 %;Sex: 73.8\
% maleNon-Hispanic Black: 21.6 %;\
Non-Hispanic White: 46.2 %; Hispanic: 29.6 %;\
Non-Hispanic Other: 2.6 %- NYC linked death certificates and medical examiner files (2005−2010)[@bib0305]Cross-sectional/ USAN: 331\
Age: Mean (SD): 48.2 (12.5);\
Sex: 68.3 % maleNon-Hispanic White: 71.0 %;\
African-American:19.9 %; Hispanic 4.2 %;Asian 2.1\
%;\
Other: 7%-California Electronic Death Reporting System (2010−2012)[@bib0310]Cross-sectional/ USAN: 573\
Age: Mean (SD): 43.5 (12);\
Sex: 72.8 % maleWhite: 50.1 %;\
Hispanic/Latino: 31.1 %;Other: 18.0\
%-Survey with people who inject drugs in San Diego, California[@bib0325]Cross-sectional/ CanadaN: 1338\
Age: NR;\
Sex: NRNR- Insite facility's on-site surveillance database[^31]Table 4Summary of Measures and Findings for Included Studies.Table 4Author (Year)Measure of SEMOpioids involvedOverdose characteristic\
(intent; type)Measure of overdoseMain findingsRisk of bias[@bib0010]SES compositePrescription & non-prescriptionIntentional & unintentional; fatalICD-10 codes for opioid poisoning deathsSocioeconomic Status: Three clusters were created from a two-step cluster analysis: *Very low SES:* persons of a younger age (15--44), lowest level of education, not participating in the workforce, some participation in shorter work-related training/support and a high level of means-tested social benefits; *Disabled*: persons of an older age (35--64), on a disability pension, low level of education, income\
higher than the minimum pension (due to the disability pension), not participating in the workforce, some in need of means-tested social welfare benefits, largest proportion of women; *Edge of the workforce* (higher SES): mainly aged 24--54 years, highest level of education, more years with income above the minimum pension, highest proportion with workforce participation and work-related training/support, less use of means-tested social welfare benefits.\
Heroin overdose death (very low SES vs. disabled vs. edge of workforce): **55.5% vs. 33.6% vs. 47.1%, p \< 0.05 in cause of death cluster**\
Heroin overdoses were most common in the very low SES cluster; other opioid overdoses were more common among those on disability and on the edge of the workforce.Poor[@bib0015]Criminal justice involvementPrescription & non-prescriptionNR; fatalICD-10 codes for opioid poisoning deathsRecent release from prison:\
Heroin-related deaths\
n; n/100,000 person-years (95 %CI)\
Overall: **18; 32 (20--50)**\
Within 2 weeks after release: **6; 409 (184--91)**\
More than 2 weeks after release: **12; 23 (14--40)**\
Methadone-related deaths\
n; n/100,000 person-years (95 %CI)\
Overall: **18; 32 (20--50)**\
Within 2 weeks after release: **5; 341 (142--818)**\
More than 2 weeks after release: **13; 23 (14--40)**\
Other opioid-related deaths\
n; n/100,000 person-years (95 %CI)\
Overall: **13; 23 (13−40)**\
Within 2 weeks after release: **5; 341 (142--818)**\
More than 2 weeks after release: **8; 14 (7−29)**Fair[@bib0020]Employment, SES composite, Criminal justice involvementNRUnintentional; fatalOpioid overdose deaths identified through Office of the Medical Examiner (OME)Unemployment rate:\
No significant associations were found between unemployment rate and overdoseFairSES composite: Including percent of persons per precinct who had less than a high school education, earned less money annually than 200 % of the federal poverty level, and received public assistance, as well as the percent of households per precinct\
with a self-reported female head of household. The composite was scored in the direction of disadvantage, with more socioeconomically disadvantaged precincts scoring higher (range 23.4--189.0).\
**Posterior median for opiate overdose: 0.35;** 95 % **credible interval: 0.05−0.64**Misdemeanor arrest rate (per 1000):\
**Posterior median for opiate overdose: 0.003;** 95 % **credible interval: 0.001−0.01**[@bib0025]Criminal justice involvementNon-prescriptionNR; fatalOpioid overdose deaths identified through OMEIncarceration in year preceding death:\
Fentanyl-related overdose in those incarcerated the year preceding death (2015 vs. 2014): **RR: 1.99, 95% CI: 1.11−3.57, p = 0.014**\
No significant differences in overdose rates were found by race/ethnicity, age, or gender over time.Poor[@bib0040]Employment, Social support,Non-prescriptionNR; non-fatalSelf-reported lifetime history of overdoseRelationship dissatisfaction:\
MV logistic regression model found that dissatisfaction with relationships predicted overdose history (**Wald-statistic 4.05, p \< 0.05**)\
No significant associations were found between employment status, social support, living alone/in temporary accommodation and overdose.Poor[@bib0030]Homelessness & Housing,\
Income and poverty,\
Employment,\
Health insurancePrescription & non-prescriptionUnintentional & undetermined; fatalICD-10 codes for opioid poisoning deathsMedian house price:\
Effect of median house price on opioid death rate:\
**−0.0121, p \< 0.05**\
The effect median house price on opioid and prescription opioid death rate estimates were only statistically significant among males (**-0.0168, p \< 0.05 and -0.0199, p \< 0.01, respectively**) but not among females.\
The effect median house price on opioid and prescription opioid death rate estimates were only statistically significant among non-Hispanic Whites **(-0.0172, p \< 0.05 and -0.0187, p \< 0.01, respectively**) but not among Black or Hispanic racial/ethnic groups.FairMedian household income:\
Effect of median house price on prescription opioid rate: **-0.0136, p \< 0.01**No significant associations were found between median household income, unemployment rate, proportion of the population with health insurance and opioid and prescription opioid overdose death.[@bib0045]SES compositePrescriptionNR; fatal & non-fatalICD-9 codes for non-fatal opioid poisonings & State death certificatesNeighborhood Deprivation Index: Neighborhood deprivation index was created based on home address and census tract variables (e.g. households in poverty) from the U.S. Census Bureau\'s 2006--2010 American Community Survey. No further information on how the index was created is provided.\
No significant associations were found between neighborhood deprivation indices and overdose.Fair[@bib0050]Criminal justice involvement, SES composite, Education, Employment, Social supportNRNR; non-fatalSelf-reported lifetime history of non-fatal opioid overdoseJail sentences over 6 months:\
**AOR: 0.70,** 95 % **CI: 0.53−0.92**PoorArea-level deprivation: Using residential postal codes, area-level deprivation score was calculated based on the Italian deprivation index at census block level. Five indicators (low level of education, unemployment, nonhome ownership, one parent\
family and overcrowding) were standardized and summed to create categorical tertiles: affluent, intermediate and deprived.\
Deprived vs. affluent: **AOR: 2.61, 95% CI: 2.25−3.02**\
Intermediate vs. affluent: **AOR: 1.09, 95% CI: 1.02−1.16**No significant associations were found between compulsory education, unemployment, family situation and overdose death.[@bib0055]Income and poverty,\
Homelessness & housing,\
Social supportPrescription & non-prescriptionUnintentional; fatalPost-mortem toxicology and autopsy reports for analgesic opioids and heroin deathsHigher median income\
(analgesic vs. heroin overdose death): **OR: 1.40; 95% CI: 1.20−1.65**\
No significant associations were found between median house income and odds of analgesic vs. non-overdose death.\
Higher income inequality\
(analgesic vs. heroin overdose death): **OR: 0.74; 95% CI: 0.61−0.91**\
No significant associations were found between income inequality and odds of analgesic vs. non-overdose death.FairDilapidated Housing Structures:\
No significant associations were found between dilapidated housing structures, and the odds of analgesic overdose vs. non-overdose deaths, and analgesic overdose vs, heroin overdose deaths.Family fragmentation (analgesic vs. non-overdose death): **OR: 1.35, 95% CI: 1.05−1.72**\
No significant associations were found between family fragmentation and odds of analgesic vs. heroin overdose deaths.[@bib0060]Social support, Education,\
EmploymentPrescription & non-prescriptionUnintentional; fatalPost-mortem toxicology and autopsy reports for deaths with at least one opioidMarital Status:\
Married (opioid overdose decedents vs. state-level population): **33.9% vs. 68.2%, p \< 0.001**FairEducational Attainment:\
Less than high school education (opioid overdose decedents vs. state-level population): **18.5% vs. 6.9%, p \< 0.001.** Graduate education (opioid overdose decedents vs. state-level population): **8.7% vs. 29.9%, p \< 0.001**Unemployment (opioid overdose decedents vs. state-level population): **64% vs. 5%, p \< 0.001**[@bib0065]Health insurancePrescriptionNR; fatal & non-fatalICD-9 codes for opioid poisoning deaths and hospitalization and ED visitsMedicaid eligibility type:\
General Assistance vs. Temporary Assistance for Needy Families: **ARR: 1.58, 95% CI: 1.28−1.94, p \< 0.001**\
Supplemental Security Income vs. Temporary Assistance for Needy Families: **ARR: 1.26, 95% CI: 1.08−1.48, p = 0.004**Good[@bib0070]Health insurancePrescriptionUnintentional; fatalICD-10 codes for opioid poisoning deathsMedicaid enrollment: Rate of deaths attributed to Prescription Opioid OD by Medicaid Status comparing the Medicaid population to anyone not enrolled in Medicaid in Washington;\
Age adjusted rate and relative risk (95 % CI):\
Medicaid vs. Non-Medicaid- **30.8; 5.7 (5.3−6.1)**\
Medicaid PRC vs. Non-Medicaid - **381.4; 92.6 (64.1−129.5)**Fair[@bib0080]Education,\
Demographics,\
Employment,\
Homelessness & housing,\
Social support, Criminal justice involvementNRNR; non-fatalSelf-reported lifetime history of non-fatal opioid overdoseEducational Attainment:\
High school completion in individuals recently released from prison (opioid overdose vs. no opioid overdose vs. no opioid use): **85% vs. 77% vs. 66%, p \< 0.001**PoorEthnicity:\
Caucasian ethnicity in individuals recently released from prison (opioid overdose vs. no opioid overdose vs. no opioid use): **82% vs. 58% vs. 25%, p \< 0.001**\
Sex:\
Female sex in individuals recently released from prison (opioid overdose vs. no opioid overdose vs. no opioid use): **47%, vs. 32% vs. 27% p \< 0.001**No significant associations found between employment status, housing situation, marital status or living situation and overdose in in individuals recently released from prison.[@bib0085]Employment,\
Criminal justice involvement,\
Health insurance,\
Social supportPrescription & non-prescriptionNR; non-fatalSelf-reported lifetime history of non-fatal opioid overdoseNo significant associations were found between employment status, incarceration in the past 30 days, health insurance status, marital status and opioid overdose.Poor[@bib0095]Income & povertyPrescription & non-prescriptionIntentional & unintentional; fatal & non-fatalICD-9 codes for opioid poisoning deaths and hospitalization and ED visitsMedian household income:\
Quartile 1 (lowest) vs. 4 (highest): AOR: **1.80, 95% CI: 1.27−2.57**\
Quartile 2 vs. 4: **AOR: 1.89, 95% CI: 1.34−2.66**\
Quartile 3 vs. 4: **AOR: 1.24, 95% CI: 1.00−1.54**Fair[@bib0100]Health insurancePrescriptionUnintentional; fatalICD-10 codes for opioid poisoning deathsMedicaid enrollment: Opioid overdose fatality rates, comparing the Medicaid population to anyone not enrolled in Medicaid in Montana;\
Overdose rates (Medicaid vs. non-Medicaid): **38.2/100,000 (30.7−45.7) vs. 4.7/100,000 (4.1−5.3)**Fair[@bib0130]Health insurance, Income & povertyPrescription & non-prescriptionIntentional & unintentional; non-fatalOpioid -related near-fatal events involving mechanical ventilation\
Opioid-related hospitalizationInsurance status:\
Medicare vs. Private: AOR:1.08, 95 % CI: 0.95−1.24\
Medicaid vs. Private: AOR:1.17, 95 % CI: 1.04−1.32\
Self-pay vs. Private: **AOR: 0.83, 95% CI: 0.75−0.93**\
Other vs. Private: **AOR:1.68, 95% CI: 1.44−1.95**PoorNo significant associations between income quartiles of residence and frequency of ED visits or hospitalizations for non-fatal overdose[@bib0140]EmploymentPrescription & non-prescriptionIntentional & unintentional; fatal & non-fatalICD-10 codes for opioid poisoning deaths\
Opioid-related ED visitsCounty-level Employment:\
Effect of unemployment rate on opioid death rate: **0.19, p \< 0.01**\
Effect of unemployment rate on opioid overdose ED visit rate: **0.95, p \< 0.01**\
State-level Employment:\
Effect of unemployment on opioid death rate: **0.33, p \< 0.01**\
Effect of unemployment on opioid overdose ED visit rate: **0.35, p \< 0.01**Good[@bib0150]Criminal justice involvement,\
Homelessness & housingPrescription & non-prescriptionNR; non-fatalSelf-reported heroin overdose in the past yearIncarceration:\
Incarceration of 5+ days: **AOR: 1.88, 95% CI: (1.04--3.40)**PoorNo permanent housing was not associated with non-fatal overdose.[@bib0175]Income & poverty,\
EducationPrescription & non-prescriptionIntentional & unintentional; fatalOpioid overdose deaths identified through coronersMedian household income:\
Adjusted Mortality Ratio (AMR; 95 % CI) for PO deaths\
**\$59,410--83,900 vs. \< \$59,410: 0.65 (0.52--0.81)**\
**\$83,910--97,460 vs. \< \$59,410: 0.58 (0.42--0.80)**\
**\$97,470 vs. \< \$59,410: 0.50 (0.33--0.74)**\
AMR (95 % CI) for heroin deaths:\
**\$97,470 vs. \< \$59,410: 0.33 (0.15--0.70)**\
% Below Poverty level:\
AMR (95 % CI) for PO deaths\
**6.35--**9.99 % **vs. \<** 6.35 %**: 1.45 (1.10--1.89)**16.86 %\
**vs. \<** 6.35 %**: 2.90 (1.02--4.68)**\
AMR (95 % CI) for heroin deaths\
16.86 % **vs. \<** 6.35 %**: 2.18 (1.02--4.68)**Fair% Higher education:\
AMR (95 % CI) for PO deaths (95 % CI)\
**41.6--**56.7 % **vs. \<** 28.0 %**: 0.59 (0.39--0.89)**56.8 %\
**vs. \<** 28.0 %**: 0.45 (0.28--0.72)**\
No significant association was found between higher education and mortality ratio for heroin deaths[@bib0180]Criminal justice involvementPrescription & non-prescriptionUnintentional; fatalPost-mortem reports for deaths with at controlled drugsIncarceration with heroin-related death:\
Prison release within 14 days of death **\[AOR (95% CI): 2.499 (1.046−5.969)\]**\
Prison release within 15−28 days of death **\[AOR (95% CI): 2.499 (1.046−5.969)\]**\
Incarceration with Methadone-related death:\
No significant association with prison release within 14 or 15−28 days of deathFair[@bib0185]Health insurance,\
Income & povertyPrescription & non-prescriptionIntentional & unintentional; fatal & non-fatalICD-9 codes for opioid poisoning deaths and hospitalization and ED visitsInsurance Status and Poverty:\
In the relationship between those who use heroin versus those who use prescription opioids, there is a significant relationship in participants aged 18−34 when participants are separated into groups based on insurance status and poverty **(p \< 0.01)** and in participants aged 35 and older when participants are separated into groups based on insurance status and poverty **(p \< 0.01)**Fair[@bib0195]Social supportPrescriptionNR; non-fatalPost-overdose reports for overdose with prescription opioidsMarital Status:\
Never Married vs. Married: **AOR: 1.35 (1.01--1.82)**\
Widowed vs. Married: **AOR: 2.04 (1.40--2.97)**Fair[@bib0205]Criminal justice involvement,\
Income& poverty,\
Homelessness & housingNon-prescriptionNR; non-fatalSelf-reported on a scale of 1−10Incarceration and Recent overdose:\
Incarcerated ≥20 months vs. Never incarcerated: **AOR (95% CI): 2.99 (1.52--5.88)**PoorSex Work:\
Ever been paid money for sex vs. No: **OR (95% CI); 1.53 (1.05−2.23)**Homelessness:\
No association between homelessness and recent overdose[@bib0210]Criminal Justice InvolvementNRNR; fatalICD-8,910 codes for opioid poisoning deathsIncarceration:\
Death from overdose during the 2 weeks after release from prison was 10 times higher (**ARR: 10.2; 95% CI: 4.4--23.9**), and in the 3-week period more than six times higher (**ARR: 6.5, 95% CI; 2.7--15.7**), than the risk during other time spent outside prison.\
In prison, however, the risk of overdose was less than 1/10^th^ of the risk outside (**ARR: 0.08, 95% CI 0.01--0.57**)Fair[@bib0225]Employment,\
EducationPrescriptionIntentional & unintentional; fatalICD-10 codes for opioid poisoning deathsUnemployment Rate:\
Unemployment rate was not associated with a decrease of opioid-related overdose deaths ratesFairEducational Attainment: Educational attainment was associated with a decrease of 0.08 opioid-related overdose deaths per 100,000 population annually **(-0.08: 95% CI: -0.40, -0.24)**[@bib0230]Social support,\
Education,\
Income & PovertyPrescriptionUnintentional; fatalICD-10 codes for opioid poisoning deathsMarital Status and College Education: The methadone group had fewer people who were married (**p = 0.024**), and fewer people who had attended college (**p = 0.048**)\
No association between type of overdose decedents and poverty rate by county.Fair[@bib0235]Income & Poverty,\
DemographicsPrescriptionNR; non-fatalICD-9 codes for opioid-related poisoningMedian Household Income:\
No association between median HH income/% of families in poverty with zip code rates of prescription opioid poising hospitalizationsGoodIndigenous ancestry:\
Association of % American Indians with zip code rates of prescription opioid poising hospitalizations **Relative Rate (95% CI): 1.015 (1.008, 1.023)**\
Association of zip code within an American Indian reservation with zip code rates of prescription opioid poising hospitalizations; **Relative Rate (95% CI): 0.473 (0.294, 0.753)**[@bib0250]SES composite,\
EmploymentPrescriptionIntentional & unintentional; fatalPost-mortem toxicology and autopsy reports for opioid-related deathsSocioeconomic Status: Socioeconomic status using residential address and the Victorian Index of Relative Socioeconomic Disadvantage. Lower scores/quintiles indicate an area has many people with low levels of education, employed in low-skill jobs, and many households with low income.\
Unintentional drug toxicity deaths: Quartile 1 vs. Quartile 4: **Rate ratio (95% CI): 3.0 (1.4--6.1)**FairEmployment status: No association between unemployed and on other government benefits versus all other employment status types with fatal drug toxicity cases involving oxycodone (2003−2009)[@bib0260]Homelessness & housing,\
Criminal Justice Involvement,\
Income & poverty,\
SES CompositeNPNR; non-fatalSelf-reported history of overdoseCurrently Homeless:\
Homeless at the time of the interview vs. not homeless: **OR (95% CI): 2.59 (1.87, 3.59)**\
Criminal Justice Measures:\
Arrested 3 or more times in the past year: **AOR (95% CI); 2.50 (1.61, 3.87)**\
No association between total length of time incarcerated and prevalence of recent OD\
Prohibited Income\
Received money or drugs in exchange for sex within the last 6 months: **OR (95% CI); 2.08 (1.38, 3.14)**\
Social Marginalization Score\
Respondents were assigned 1 point for each of the following variables they reported: being currently homeless; spending 5 or more years in jail, identifying as lesbian, gay, bisexual, or transgender, and engaging in sex work for money or drugs in the past 6 months. For each additional characteristic that a participant reported, the likelihood of associated overdose increased in a stepwise fashion. One point: **OR (95% CI); 2.33 (1.46, 3.72)** Two points: **OR (95% Cl); 3.73 (2.27, 6.14)** Three points or more: **OR (95% Cl); 6.76 (3.45, 13.2)**Poor[@bib0265]Social SupportPrescription & non-prescriptionUnintentional; fatalPost-mortem toxicology and autopsy reports for opioid-related deathsMarital Status:\
Decedents who died from methadone co-intoxication with prescription drugs were significantly more likely to be living with a partner or married **(44.1% versus 29.0%** for methadone alone and **25.0%** for methadone and illicit drugs) **p \< 0.05**Fair[@bib0270]Health insurancePrescription & non-prescriptionNR; fatalICD-10 codes for opioid poisoning deathsMedicaid Status:\
Rate ratios comparing death rates between 2003 and 2012: Medicaid: **5.3;** Non-Medicaid: **3.9**\
Deaths per 100,000 among all New York state residents not enrolled in Medicaid increased from **0.73 in 2003 to 2.82 in 2012**, while among Medicaid enrollees, the rates increased from **1.57 to 8.31** over the same period.\
New York state Medicaid enrollees had higher death rates for opioid analgesic poisonings than did those not enrolled in Medicaid, and the differences increased over time.Fair[@bib0275]Homelessness & housing,\
Education,\
Criminal justice involvement,\
EmploymentNRNR; non-fatalSelf-reported history of overdoseHomelessness:\
Homeless in the past 6 months vs. not homeless in overdose: **AOR (95% CI): 2.9 (1.5, 5.7)**PoorNo significant association between education/recent incarceration/employment and overdose[@bib0280]Education,\
Income & povertyPrescription & non-prescriptionUnintentional; fatalICD-10 codes for opioid poisoning deathsEducation:\
Unintentional opioid overdose deaths with Education:\
College or more vs. less than high school: **AOR (95% CI): 2.13 (1.44, 3.16)**GoodNo significant association between neighborhood poverty and unintentional opioid overdose[@bib0305]Income & povertyPrescription & non-prescriptionUnintentional; fatalPost-mortem toxicology and autopsy reports for opioid-related deathsPoverty:\
Decedents above poverty line (%)/decedents below poverty line (%) by race: Decedents below the poverty line were more likely to be African-American (**23.2 % compared to 11.9%, p = 0.03**)\
Decedent age and sex distributions were similar across areas above and below the poverty lineFair[@bib0310]Homelessness & housing\
Criminal justice involvementPrescription & non-prescriptionNR; non-fatalSelf-reported history of overdoseHomelessness:\
Homeless in the past 6 months:\
≥1 overdose in the past six months: 35 (77.8 %)\
No overdoses in the past six months: 315 (59.7 %) **p = 0.02**PoorCriminal justice measures:\
Arrested for drug possession in the past 6 months: **AOR (95% CI); 5.17 (2.37, 11.24)**\
≥1 OD in the past six months vs. No OD in past 5 months\
Arrested: 19 (43.2 %) vs. 135 (25.7 %); **p = 0.02**\
Arrested for drug possession 12 (27.3 %) vs. 38 (7.3 %) **p \< 0.001**\
Police presence caused hurried or rushed injection 18 (40.9 %) vs. 133 (25.3 %); **p = 0.03**\
No association between being somewhat/very fearful that police are going to arrest or interfere with drug use, having their syringes confiscated by police.[@bib0325]Income & povertyPrescription & non-prescriptionNR; non-fatalPost-overdose reports for opioid-related ODsIncome Assistance:\
The risk of overdose for those injecting on the three days beginning with cheque day was significantly higher than for those injecting on other days; **OR (95% CI): 2.06 (1.80--2.36)**\
The risk of overdose on the three days beginning with cheque day was significantly higher for those injecting opioids alone; **OR (95% CI): 2.16 (1.83--2.55)**\
Exclusive opioid use was reported in 66 % of overdoses that occurred on the three days beginning with cheque day, while 75 % of overdoses on other days involved opioid use; **OR (95% CI): 0.63 (0.47--0.84)**Fair[^32]Fig. 2Aggregate Risk of Bias Plot for Observational Cohort and Cross-Sectional Studies.Fig. 2

3.3. Dimensions of SEM {#sec0040}
----------------------

### 3.3.1. Criminal justice system involvement {#sec0045}

Criminal justice system involvement was included as a measure of SEM due to the close link between socioeconomic precarity and incarceration as well as the economic and social constraints that are experienced post-release. Most studies with measures of criminal justice system involvement (11/13) found a significant positive association between these measures and overdose ([@bib0015]; [@bib0020]; [@bib0025]; [@bib0050]; ; [@bib0150]; [@bib0180]; [@bib0205]; [@bib0210]; [@bib0260]; [@bib0310]) where overdose occurred at higher rates or with greater odds after release from prison. Most studies operationalized criminal justice system involvement as recent incarceration (yes/no), however some also looked at length of time incarcerated ([@bib0025]; [@bib0205]; [@bib0260]), time since release ([@bib0015]; [@bib0025]; [@bib0180]; [@bib0210]), misdemeanor arrest rates ([@bib0020]), or outcomes for those under community supervision ([@bib0080]).

### 3.3.2. Income and poverty {#sec0050}

Nearly two-thirds (8/13) of the studies included in our review with income or poverty-related variables found a significant positive association between measures of poverty and overdose outcomes ([@bib0055]; [@bib0095]; [@bib0175]; [@bib0185]; [@bib0205]; [@bib0260]; [@bib0305]; [@bib0325]). The majority of studies operationalized income through either neighborhood-level poverty rate or median household income, with two studies looking at prohibited income generation activities (i.e., sex work), and one study looking at income disbursement. Two studies included measures of income or poverty and its intersections with race/ethnicity.

### 3.3.3. Employment {#sec0055}

Two of eleven of the studies with measures of unemployment found a significant positive association with overdose, where higher levels of unemployment were associated with higher overdose rates ([@bib0060]; [@bib0140]). Most of the studies not finding conclusive evidence to support employment being associated with overdose. Half of the studies operationalized employment using unemployment rates at the county or state level, while the other half used measures of individual employment status, most commonly comparing those who were employed to those who were unemployed.

### 3.3.4. Social support {#sec0060}

Articles including measures of social support were included to address the element of SEM related to social exclusion or isolation. A total of six of the nine studies including measures of social support that were included in our review found a significant negative association to be present between the measures of social support that they included and the overdose outcome investigated ([@bib0040]; [@bib0055]; [@bib0060]; [@bib0195]; [@bib0230]; [@bib0265]). Six of the included studies operationalized social support with measures of marital status at the individual level ([@bib0060]; [@bib0080]; [@bib0085]; [@bib0195]; [@bib0230]; [@bib0265]), three studies included measures of living arrangements at the individual level ([@bib0040]; [@bib0050]; [@bib0085]), one study included perceived social support and relationship status, ([@bib0040]), and one study used a state-level measure of family fragmentation ([@bib0055]).

### 3.3.5. Health insurance {#sec0065}

Studies that included measures of health insurance status were included, based on the close connection between health insurance and socioeconomic status (SES) in the US, and the access to health care that insurance provides. For studies of health insurance, six of eight papers reviewed found significant associations between measures of health insurance and opioid overdose ([@bib0070]; [@bib0100]; [@bib0130]; [@bib0065]; [@bib0185]), where insurance type (enrollment in or eligibility for Medicaid in most cases) was positively associated with overdose. All of the included studies had samples from the US population, and all of them except one ([@bib0030]) measured health insurance at the individual level, typically comparing those with Medicaid to those with other types of insurance or to a non-Medicaid population. All but one study used administrative data to link health insurance to overdose, and the study that used self-reported insurance and overdose history did not find evidence of a significant association ([@bib0085]). Notably, both studies that failed to find an association used measures of uninsured vs. insured status. In contrast, the remaining six studies included multiple insurance types, examining overdose outcomes recorded in administrative databases.

### 3.3.6. Homelessness and housing status {#sec0070}

Overall, four of the eight studies including measures of housing reported significant negative associations between measures of housing status/homelessness and opioid overdose outcomes ([@bib0260]; [@bib0030]; [@bib0275]; [@bib0310]), where homelessness and lower housing prices were associated with higher rates of overdose. Two of these measured housing status at a population level with one measuring state-level housing status as median household price ([@bib0030]) and the other measuring neighborhood-level dilapidated housing structures ([@bib0055]). These same two studies obtained measures of fatal overdose through administrative data linkages. The remaining six studies obtained individual self-reported measures of homelessness and non-fatal overdose.

### 3.3.7. Education {#sec0075}

Six of eight of the studies included in our review found a significant negative association between measures of education and overdose ([@bib0080]; [@bib0060]; [@bib0175]; [@bib0225]; [@bib0230]; [@bib0280]) where, in most cases, higher levels of educational attainment were associated with lower rates of opioid-related fatal overdose. Two of the included studies collected educational attainment data at the zip code or state level while six studies used measures of individual educational attainment.

### 3.3.8. Socioeconomic status or deprivation composite measures {#sec0080}

A total of five out of six of the studies included in our review investigating SES found a significant negative association between the combined measures of SES that they included, and the overdose outcome investigated ([@bib0050]; [@bib0260]; [@bib0250]; [@bib0010]; [@bib0020]) where low SES was associated with higher rates of overdose. Each of the six included studies operationalized composite SES measures differently, introducing slightly different combination of measures of income, employment, and education. Four of these studies examined deprivation variables at the population level ([@bib0045]; [@bib0250]; [@bib0010]; [@bib0020]) while two studies used measures of participant characteristics or SES at the individual level ([@bib0050]; [@bib0260]).

4. Discussion {#sec0085}
=============

4.1. Summary of findings {#sec0090}
------------------------

Of the studies that yielded significant findings, all but one found results linking socioeconomic factors and overdose in the hypothesized direction, whereby increased vulnerability was associated with a higher rate or increased likelihood of overdose. Six out of eight dimensions of SEM had significant, positive associations with opioid overdose in most studies that investigated them, including insurance status, criminal justice involvement, education, social support, income, and SES composite measures. These results are consistent with a growing body of literature that connects aspects of marginalization and drug-related harm ([@bib0005]; [@bib0110]; [@bib0120]; [@bib0135]; [@bib0170]; [@bib0285]; [@bib0290]; [@bib0050]; [@bib0260]) and is indicative of the precarity and risk that people who use opioids experience when they are socially and economically marginalized.

Our review revealed strong connections between socioeconomic factors and overdose in multiple substantive domains. For example, receiving state-funded health insurance is associated with increased risk of overdose, likely because it is associated with low income. Overdose is also a more common occurrence for those recently released from prison and for those who have a history of incarceration. Having social support in the form of being in a relationship was inversely associated with overdose, as was having higher levels of educational attainment. Composite measures of SES show that experiencing hardship across multiple indicators of social and economic well-being is positively associated with overdose. Finally, overdose rates are higher in low income areas and in situations where people are living in poverty, and racialized populations are more highly represented in low-income overdose fatality rates than non-racialized populations. In this review we therefore find evidence to suggest that aiming to decrease socioeconomic disadvantage may be an important part of tackling the opioid overdose crisis.

Risk of bias, measurement limitations, and analytic issues demonstrate why caution should be exercised in the interpretation of a lack of consistent association with overdose in the two areas of SEM where less than half of studies found significant relationships: employment and housing/homelessness. In several cases, reviewed articles did not find significant relationships between employment and overdose, and as many of the studies reported aggregate measures, it is difficult to know what is underlying these findings. Extant literature robustly demonstrates the labour market exclusion experienced by people who use drugs, and stands in contrast with the findings of these two elements of the review, where previous studies that have assessed job precarity, job type, and other income-generation practices for people who use drug and found associations with drug-related harm ([@bib0240]; [@bib0245]). Similarly, prior studies have shown that the stigmatizing experience of being unstably housed exposes individuals to social harms that may elevate risk of overdose such as exposure to verbal and physical assault, lack of access to safe space, street-based activities, and social exclusion ([@bib0105]). In our review, some studies indicated that being homeless or living in an area with low housing prices is associated with increased likelihood of overdose, but such associations were present in only half of the studies that examined housing status/homelessness.

4.2. Limitations of the evidence included in the review {#sec0095}
-------------------------------------------------------

We reviewed literature on a wide range of socioeconomic factors and opioid overdose. In many cases, these factors are interrelated and difficult to separate, leading to difficulty in ascertaining which aspects of social and economic marginalization are the most strongly associated with overdose. For example, the associations present in studies in the health insurance category that compared overdose rates for those enrolled in Medicaid compared to those not enrolled in Medicaid, may have also been reflecting the income differences between these two populations due to low income being a key criterion for Medicaid eligibility. From a specificity perspective, this is a limitation, however, it also reflects how interconnected social and economic factors are, and demonstrates the value in taking a broad approach to the definition of socioeconomic marginalization.

To make the results of our review widely applicable and of maximal use to those making decisions in the overdose crisis, we chose to include studies with any type of overdose measure in the review. By undertaking a broad review, we were able to explore whether the effects of SEM were similar across different elements of SEM, different settings, and different populations. A narrower review would have greatly reduced included studies and may have been more susceptible to erroneous conclusions based on bias ([@bib0115]). However, including a variety of outcome measures also presents limitations, including the inability to identify unique risks from different outcomes (e.g., fatal and non-fatal overdose) and the inability to conduct statistical meta-analyses. Following the results of this broad initial review on SEM and overdose, future researchers would do well to carry out explicit a priori subgroup analyses with more narrowly defined outcome measures.

Our review of SEM and opioid overdose revealed an evidence base that is underdeveloped. Many studies included in our review were not designed in ways that could reliably rule out confounding variables and had threats to validity that affected the interpretation of results. Moreover, several of these same studies measured social or economic factors and overdose using overlapping, poorly specified or inappropriate time frames that could mask potentially real associations. Many of the studies that looked at fatal overdose relied on administrative datasets that did not have suitable operationalization of the measures of SEM included or were primarily interested in other (non-SEM) independent variables and therefore had limited conceptual or methodological consideration for inclusion of indicators of SEM (i.e., inclusion as control variables). Other studies included measures of socioeconomic factors only in descriptive or bivariate analyses. Although we were hoping to analyze marginalization and overdose, most studies merely allowed us to draw conclusions about socioeconomic factors and were designed such that it is difficult to determine the true root causes. The results of this review indicate the difficulty present in statistically linking distal, upstream social and socioeconomic determinants to an acute health event such as overdose and highlight the need for more robust research methods than those commonly used to investigate these connections.

4.3. Policy implications and recommendations for future research {#sec0100}
----------------------------------------------------------------

Despite the multiple socioeconomic factors that were included in the search protocol of this review, there were no studies that directly measured the impact of drug enforcement and policing, the density of alcohol outlets, money lending services, housing availability and affordability, material factors (such as food security, service access), policy (such as drug policy, income or employment support policy), or social stigma on opioid overdose outcomes. These evidence gaps represent important elements of marginalization that may impact overdose outcomes for people who use opioids and could significantly help to guide the development of effective policies to prevent overdose. There is a critical need for well-designed studies that explicitly and comprehensively examine the association between SEM variables and overdose as their primary purpose.

Furthermore, very few studies reported on the different ways that SEM affects those across varying ethnic backgrounds, gender, sexual orientation among other marginalized or oppressed social statuses. Few studies looked at combined measures of SEM or the experience of multiple elements of social and economic marginalization simultaneously. Given the tendency for these factors to co-occur and the potential relevance of intersectional disadvantage, research studies that can robustly include multiple measures of SEM are important to avoid incorrectly attributing associations to the included measures that may in fact be due to other omitted variables.

Given the ongoing overdose crisis, focused research that is designed to be more applicable to policy and programmatic prevention of overdose and drug-related harm is needed. The COVID-19 pandemic and the associated mitigation strategies have the potential to further exacerbate the overdose crisis, through increased SEM. This indicates an urgent need for policies that better support the social and economic security of people who use opioids, and research that can support such decision-making. Studies designed to inform decision making around upstream determinants of health in response to the overdose crisis and the COVID-19 pandemic could be especially valuable for policy makers and program managers working to combat overdose. This includes research that strengthens inference, for example, by using specific and meaningful measures, comparative research designs, and natural experiments. Nevertheless, the studies included in this review found results in the hypothesized direction in most cases, where increasing social and economic precarity was associated with increased fatal and non-fatal overdose for people who use opioids. This suggests that initiatives targeting health equity and aiming to decrease socioeconomic marginalization are a valuable and necessary part of combatting the overdose crisis and should be part of strategic planning for overdose prevention.
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[^1]: Notes: \*Terms related to these key concepts were entered into all computer databases, combined using appropriate Boolean operators. All terms were searched both as subject headings as well as key words. See Appendix A for a summary of the Medline search terms included.

[^2]: Notes: Y = yes, N = no, CD = cannot determine, NR = not reported, N/A = not applicable.

[^3]: \*Domains 1--14 for Studies Assessed with the Quality Assessment Tool for Observational Cohort and Cross-Sectional Studies).

[^4]: D1. Was the research question or objective in this paper clearly stated?

[^5]: D2. Was the study population clearly specified and defined?

[^6]: D3. Was the participation rate of eligible persons at least 50 %?

[^7]: D4. Were all the subjects selected or recruited from the same or similar populations (including the same time period)? Were inclusion and exclusion criteria for being in the study prespecified and applied uniformly to all participants?

[^8]: D5. Was a sample size justification, power description, or variance and effect estimates provided?

[^9]: D6. For the analyses in this paper, were the exposure(s) of interest measured prior to the outcome(s) being measured?

[^10]: D7. Was the timeframe sufficient so that one could reasonably expect to see an association between exposure and outcome if it existed?

[^11]: D8. For exposures that can vary in amount or level, did the study examine different levels of the exposure as related to the outcome (e.g., categories of exposure, or exposure measured as continuous variable)?

[^12]: D9. Were the exposure measures clearly defined, valid, reliable, and implemented consistently across all study participants?

[^13]: D10. Was the exposure(s) assessed more than once over time?

[^14]: D11. Were the outcome measures (dependent variables) clearly defined, valid, reliable, and implemented consistently across all study participants?

[^15]: D12. Were the outcome assessors blinded to the exposure status of participants?

[^16]: D13. Was loss to follow-up after baseline 20 % or less?

[^17]: D14. Were key potential confounding variables measured and adjusted statistically for their impact on the relationship between exposure(s) and outcome(s)?

[^18]: \^Domains 1--12 for Studies Assessed with the Quality Assessment Tool for Case Control Studies.

[^19]: D1. Was the research question or objective in this paper clearly stated and appropriate?

[^20]: D2. Was the study population clearly specified and defined?

[^21]: D3. Did the authors include a sample size justification?

[^22]: D4. Were controls selected or recruited from the same or similar population that gave rise to the cases (including the same timeframe)?

[^23]: D5. Were the definitions, inclusion and exclusion criteria, algorithms or processes used to identify or select cases and controls valid, reliable, and implemented consistently across all study participants?

[^24]: D6. Were the cases clearly defined and differentiated from controls?

[^25]: D7. If less than 100 percent of eligible cases and/or controls were selected for the study, were the cases and/or controls randomly selected from those eligible?

[^26]: D8. Was there use of concurrent controls?

[^27]: D9. Were the investigators able to confirm that the exposure/risk occurred prior to the development of the condition or event that defined a participant as a case?

[^28]: D10. Were the measures of exposure/risk clearly defined, valid, reliable, and implemented consistently (including the same time period) across all study participants?

[^29]: D11. Were the assessors of exposure/risk blinded to the case or control status of participants?

[^30]: D12. Were key potential confounding variables measured and adjusted statistically in the analyses? If matching was used, did the investigators account for matching during study analysis?

[^31]: \*Aggregate data collected at police precinct level.

[^32]: Statistically significant results denoted in bold.
